Announcement • Jul 15

Bioadaptives Inc Announces Commercial Availability of Xcellaraheart Cardiovascular Wellness Formula

BioAdaptives Inc. announced the upcoming commercial availability of XcellaraHeart, a premium cardiovascular wellness formula that integrates two complementary areas of cellular health science: stem/progenitor cell mobilization and cardiovascular repair signaling support. XcellaraHeart is built on the Company’s Xcellara base, which is supported by a randomized, double-blind, placebo-controlled human clinical trial documenting an average 268.8% increase in circulating primitive stem/progenitor-type cells after four weeks. The Company believes this clinical result provides a strong foundation for XcellaraHeart’s supply-side strategy: maintaining a healthy circulating pool of stem/progenitor-type cells. The second component of the formula is Tanshinone IIA, a natural bioactive compound derived from Danshen root (Salvia miltiorrhiza). Tanshinone IIA has been studied in peer-reviewed cardiovascular research for its effects on the SDF-1a/CXCR4 chemokine axis, a signaling pathway linked to cellular trafficking, cardiovascular repair biology, and tissue-specific signaling. XcellaraHeart was developed around a two-part cardiovascular-wellness strategy: 1) Supply: The Xcellara base is supported by a randomized, double-blind, placebo-controlled human clinical trial showing an average 268.8% increase in circulating primitive stem/progenitor-type cells after four weeks. 2) Signaling: Tanshinone IIA has been studied for its effects on the SDF-1a/CXCR4 signaling pathway, which is associated with cellular trafficking and cardiovascular repair-response biology. BioAdaptives developed XcellaraHeart based on the hypothesis that increasing circulating stem/progenitor-type cells may be more meaningful when paired with nutrients that support tissue-specific signaling pathways. The Company believes Tanshinone IIA is a particularly compelling candidate for cardiovascular wellness because of its long research history and published evidence on cardiovascular signaling pathways. The complete scientific evidence dossier for the formulation is available. The dossier will separate findings from BioAdaptives’ human clinical research on the Xcellara base, published research on Tanshinone IIA, and the Company’s product-development rationale for combining the two. XcellaraHeart will be available for order starting Aug. 1, 2026, with first deliveries expected in early August. General information on new products awaiting rollout is available. BioAdaptives Inc. is the developer of the Xcellara line of stem cell mobilization and tissue-homing supplements. The Company’s flagship Xcellara base formula is the only dietary supplement with a human randomized, double-blind, placebo-controlled clinical trial demonstrating a 268.8% increase in circulating hematopoietic stem and progenitor cells at four weeks with zero adverse effects on more than twenty blood parameters. The Xcellara product line includes seven targeted formulas combining the clinically proven mobilization base with tissue-specific signaling ingredients for cardiac, joint, neural, dermal, longevity, and stress-resilience applications. The complete scientific evidence dossier for the XcellaraHeart formulation will be available. The dossier separates what has been demonstrated in BioAdaptives’ human clinical research on the Xcellara base from published research on Tanshinone IIA and from the Company’s product-development rationale for combining the two. XcellaraHeart will be available for order starting August 1, 2026, with first deliveries expected soon after. General information on new products awaiting rollout is available. These statements have not been evaluated by the Food and Drug Administration. XcellaraHeart is not intended to diagnose, treat, cure, or prevent any disease. Xcellara is a trademark of BioAdaptives Inc.

BioAdaptives, Inc. Stock Price

BDPT Share Price Performance

BDPT Community Narratives

Trending Discussion

Recently Updated Narratives

Snowflake Analysis

BioAdaptives, Inc. Key Details

About BDPT

Recent BDPT News & Updates

BioAdaptives, Inc. announced delayed 10-Q filing

BioAdaptives Outlines Xcellara Platform Strategy And Announces Commercial Launch Of XcellaraHeart

Bioadaptives Inc Announces Commercial Availability of Xcellaraheart Cardiovascular Wellness Formula

Recent updates

BioAdaptives, Inc. Competitors

EQ Energy Drink

NuVim

Limitless Venture Group

Functional Brands